Angiotech Pharmaceuticals, Inc. (Angiotech) is a specialty pharmaceutical company focused on developing and commercializing technologies that improve the performance of medical devices and the outcomes of surgical procedures. The Company's first commercial product is a paclitaxel-eluting coronary stent system for the treatment of coronary artery disease. This product was developed based on the discovery that the drug paclitaxel blocks a cellular pathway involved in scar formation. The Taxus paclitaxel-eluting coronary stent incorporates Angiotech's technology, and is sold by its partner Boston Scientific Corporation (Bsc). On March 23, 2006, it completed the acquisition of American Medical Instruments Holding Inc. (Ami). The Company completed the acquisition of Quill Medical, Inc., including all of its technology and intellectual property in June 2006.